Thalidomide-induced limb defects: Resolving a 50-year-old puzzle

BioEssays

Volumn 31, Issue 12, 2009, Pages 1327-1336

  Vargesson, Neil ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antiangiogenesis; Chick limb development; CPS49; Phocomelia; Thalidomide analogue; Therapeutics

Indexed keywords

5' HYDROXYTHALIDOMIDE; CPS 49; DNA; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 8; HOX PROTEIN; LENALIDOMIDE; NERVE CELL ADHESION MOLECULE; SOMATOMEDIN C; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARM MALFORMATION; ARTICLE; CHONDROGENESIS; DNA DRUG COMPLEX; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYOPATHY; HUMAN; IMMUNOMODULATION; INCIDENCE; LEG MALFORMATION; LIMB DEFECT; LIMB MALFORMATION; MULTIPLE MYELOMA; MUTAGENICITY; NEUROTOXICITY; NONHUMAN; PHOCOMELIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; TERATOGENESIS; TERATOGENICITY;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIMB DEFORMITIES, CONGENITAL; THALIDOMIDE;

EID: 73149091643     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900103     Document Type: Article

References (102)

1. Franks ME, MacPherson GR, Figg WD. 2004. Thalidomide Lancet 363: 1802-11.
2. Bartlett JB, Dredge K, Dalgleish AG. 2004. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-22.
3. Teo SK, Stirling DI, Zeldis JB. 2005. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 10: 107-14.
4. Smithells RW, Newman CGH. 1992. Recognition of thalidomide defects. J Med Genet 29: 716-23.
5. Lenz WA. 1988. A short history of thalidomide embryopathy. Teratology 38: 203-15.
6. Stephens TD, Bunde CJW, Fillmore BJ. 2000. Mechanism of action in thalidomide teratogenesis. Biochem Pharm 59: 1489-99.
7. Matthews SJM, McCoy S. 2003. Thalidomide: a review of approved and investigational uses. Clin Ther 25: 342-95.
8. McBride WB. 1961. Thalidomide and congenital abnormalities. Lancet 2: 1358.
9. Lenz W, Knapp K. 1962. Foetal malformations due to thalidomide. Ger Med Mon 7: 253-58.
10. Leck IM, Millar ELM. 1962. Incidence of malformations since the introduction of Thalidomide. Br Med J 16-20.
11. Newman CG. 1977. Clinical observations on the thalidomide syndrome. Proc R Soc Med 70: 225-27.
12. Miller MT, Stromland K. 1999. Teratogen update: Thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60: 306-21.
13. Newman CG. 1986. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 13: 555-73.
14. James WH. 1965. Teratogenic properties of thalidomide. Br Med J 2: 1064.
15. Kajii T, Kida M, Takahashi K. 1973. The effect of Thalidomide intake during 113 human pregnancies. Teratology 8: 163-66.
16. Galustian C, Labarthe MC, Bartlett JB, et al. 2004. Thalidomidederived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 4: 1963-70.
17. Galustian C, Dalgleish A. 2009. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 10: 125-33.
18. Gordon JN, Goggin PM. 2003. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 79: 127-32.
19. Stephens TD, Fillmore BJ. 2000. Hypothesis: Thalidomide embryopathy - Proposed mechanism of action. Teratology 61: 189-95.
20. Calabrese L, Fleischer AB. 2000. Thalidomide: current and potential applications. Am J Med 108: 487-95.
21. Castilla E, Ashton-Prolla P, Barreda-Mejia E, et al. 1996. Thalidomide, a current teratogen in South America. Teratology 54: 273-77.
22. Schuler-Faccini L, Soares RC, de Sousa AC, et al. 2007. New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79: 671-72.
23. Williams RT. 1963. Teratogenic effects of thalidomide and related substances. Lancet 1: 723-24.
24. Ando Y, Fuse E, Figg WD. 2002. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8: 1964-73.
25. Tseng S, Pak G, Washenik K, et al. 1996. Rediscovering Thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 35: 969-79.
26. Braun AG, Harding FA, Weinreb SL. 1986. Teratogen metabolism: Thalidomide activation is mediated by Cytochrome P-450. Toxicol Appl Pharmacol 82: 175-79.
27. Dredge K, Horsfall R, Robinson SP, et al. 2005. Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69: 56-63.
28. Price DK, Ando Y, Kruger EA, et al. 2002. 5′-OH thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 24: 104-10.
29. Ng SSW, Gutschow M, Weiss M, et al. 2003. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63: 3189-94.
30. Ng SS, MacPherson GR, Gutschow M, et al. 2004. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 10: 4192-97.
31. Lepper ER, Smith NF, Cox MC, et al. 2006. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 7: 677-85.
32. Warfel NA, Lepper ER, Zhang C, et al. 2006. Importance of the stress kinase p38 in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res 12: 3502-09.
33. Lepper ER, Ng S, Gutschow M, et al. 2004. Comparative molecular field analysis and comparative molecular similarity indices analysis of Thalidomide analogues as angiogenesis inhibitors. J Med Chem 47: 2219-27.
34. Therapontos C, Erskine L, Gardner E, et al. 2009. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106: 8573-79.
35. Boylen JB, Horne HH, Johnson WJ. 1963. Teratogenic effects of thalidomide and related substances. Lancet 1: 552.
36. Jurand A. 1966. Early changes in limb buds of chick embryos after thalidomide treatment. J Embryol Exp Morphol 16: 289-300.
37. Tamilarasan KP, Kolluru GK, Rajaram M, et al. 2006. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 7: 17.
38. Knobloch J, Shaughnessy JD Jr, Ruther U. 2007. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signalling pathway. FASEB J 21: 1410-21.
39. Fratta ID, Sigg EB, Maiorana K. 1965. Teratogenic effect of thalidomide in rabbits, rats, hamsters and mice. Toxicol Appl Pharmacol 7: 268-86.
40. Fox RR, Sawin PB, Crary DD, et al. 1966. Intravenous injection of thalidomide in pregnant rabbits. Science 154: 1362.
41. Neubert R, Hinz N, Thiel R, et al. 1996. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of Thalidomide. Life Sci 58: 295-316.
42. Stephens TD. 1988. Proposed mechanisms of action in Thalidomide embryopathy. Teratology 38: 229-39.
43. D'Amato RJ, Loughnan MS, Flynn E, et al. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082-85.
44. Hansen JM, Harris C. 2004. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 6: 1-14.
45. Knobloch J, Schmitz I, Gö tz K, et al. 2008. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28: 529-38.
46. Vicente-Manzanares M, Choi C-K, Horwitz AR. 2009. Integrins in cell migration - the actin connection. J Cell Sci 122: 199-206.
47. Thiele A, Thormann M, Hofmann H-J, et al. 2000. A possible role of Ncadherin in thalidomide teratogenicity. Life Sci 67: 457-61.
48. Tabin CJ. 1998. A developmental model for thalidomide defects. Nature 396: 322-23.
49. McCredie J, McBride WG. 1973. Some congenital abnormalities: possibly due to embryonic peripheral neuropathy. Clin Radiol 24: 204-11.
50. McCredie J, North K, de Longh R. 1984. Thalidomide deformities and their nerve supply. J Anat 139: 397-410.
51. Harsum S, Clarke JD, Martin P. 2001. A reciprocal relationship between cutaneous nerves and repairing skin wounds in the developing chick embryo. Dev Biol 238: 27-39.
52. Luria V, Krawchuk D, Jessell TM, et al. 2008. Specification of motor axon trajectory by ephrin-B: EphB signaling: symmetrical control of axonal patterning in the developing limb. Neuron 60: 1039-53.
53. Strecker TR, Stephens TD. 1983. Peripheral nerves do not play a trophic role in limb skeletal morphogenesis. Teratology 27: 159-167.
54. Swanson GJ. 1985. Paths taken by sensory nerve fibres in aneural chick wing buds. J Embryol Exp Morphol 86: 109-24.
55. Jonsson NA. 1972. Chemical structure and teratogenic properties. IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm Suec 9: 543-62.
56. Ashby J, Tinwell H, Callander RD, et al. 1997. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat Res 396: 45-64.
57. Strömland K, Philipson E, Grönlund MA. 2002. Offspring of male and female parents with thalidomide embryopathy: birth defects and functional anomalies. Teratology 66: 115-21.
58. Kohlhase J, Schubert L, Liebers M, et al. 2003. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acrorenal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy. J Med Genet 40: 473-8.
59. Kohlhase J, Holmes LB. 2004. Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by Thalidomide. Birth Defects Res Part A 70: 550-51.
60. Wolpert L, Tickle C, Sampford M. 1979. The effect of cell killing by Xirradiation on pattern formation in the chick limb. J Embryol Exp Morph 50: 175-98.
61. Galloway JL, Delgado I, Ros MA, et al. 2009. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 460: 400-4.
62. Neubert D. 1997. Never ending tales of the mode of action of thalidomide. Teratog Carcinog Mutagen 17: i-ii.
63. Neubert R, Merker HJ, Neubert D. 1999. Developmental model for thalidomide action. Nature 400: 419-20.
64. Newman CG. 1985. Teratogen update: clinical aspects of thalidomide embryopathy-a continuing preoccupation. Teratology 32: 133-44.
65. Henkel L, Willert H. 1969. Dysmelia - a classification and a pattern of malformation in a group of congenital defects of the limbs. J Bone Joint Surg 51B: 399-414.
66. Smithells RW. 1973. Defects and disabilities of thalidomide children. BMJ 1: 26-72.
67. Tabin C, Wolpert L. 2007. Rethinking the proximodistal axis of the vertebrate limb in the molecular era. Genes Dev 21: 1433-42.
68. Towers M, Tickle C. 2009. Generation of pattern and form in the developing limb. Int J Dev Biol 53: 805-12.
69. Vargesson N, Laufer E. 2001. Smad7 misexpression during embryonic angiogenesis causes vascular dilation and malformations independently of vascular smooth muscle cell function. Dev Biol 240: 499-516.
70. Vargesson N. 2003. Vascularisation of the developing chick limb bud: role of the TGFβ signalling pathway. J Anat 202: 93-103.
71. Martin GR. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 12: 1571-86.
72. Sun X, Mariani FV, Martin GR. 2002. Functions of FGF signaling from the apical ectodermal ridge in limb development. Nature 418: 501-8.
73. Mariani FV, Ahn CP, Martin GR. 2008. Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning. Nature 453: 401-5.
74. Smithells RW, Leck I. 1963. The incidence of limb and ear defects since the withdrawal of thalidomide. Lancet 1095-97.
75. Sauer H, Gunther J, Hescheler J, et al. 2000 Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathology 156: 151-8.
76. Bauer KS, Dixon SC, Figg WD. 1998. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827-34.
77. Schumacher H, Smith RL, Williams RT. 1965. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother 25: 338-51.
78. Schumacher H, Blake DA, Gurian JM, et al. 1968. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160: 189-200.
79. Kenyon BM, Browne F, D'Amato RJ. 1997. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularisation. Exp Eye Res 64: 971-78.
80. Marks MG, Shi J, Fry MO, et al. 2002. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull 25: 597-604.
81. Lu J, Helsby N, Palmer BD, et al. 2004. Metabolism of thalidomide in liver microsomes of mice, rabbits and humans. J Pharmacol Exp Ther 310: 571-77.
82. Ishida S, Usui T, Yamashiro K, et al. 2003. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198: 483-9.
83. Saint-Geniez M, D'Amroe PA. 2004. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 48: 1045-8.
84. Michaelis M, Michaelis UR, Fleming I, et al. 2004. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-7.
85. Whitsel AI, Johnson CB, Forehand CJ. 2002. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 66: 153-63.
86. Holmes LB. 2002. Teratogen-induced limb defects. Am J Med Genet 112: 297-303.
87. Woolf AS, Gnudi L, Long DA. 2009. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 20: 239-44.
88. Brennan J, Karl J, Capel B. 2002. Divergent vascular mechanisms downstream of Sry establishe the arterial system in the XY gonad. Dev Biol 244: 418-28.
89. Carmeilet P, Tessier-Lavigne M. 2005. Common mechanisms of nerve and blood vessel wiring. Nature 436: 193-200.
90. Vacca A, Scavelli C, Montefusco V, et al. 2005. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23: 5334-46.
91. Yabu T, Tomimoto H, Taguchi Y, et al. 2005. Thalidomide-induced antiangiogenic action is mediated through depletion of VEGF receptors, and is antagonized by spingosine-1-phosphate. Blood 106: 125-34.
92. Kumar S, Raje N, Hideshima T, et al. 2005. Antimyeloma activity of two novel N substituted and tetrafluorinated thalidomide analogs. Leukemia 19: 1253-61.
93. Hansen JM, Gong S-G, Philbert MA, et al. 2002. Misregulation of gene expression in the redox-sensitive NF-kB-dependent limb outgrowth pathway by thalidomide. Dev. Dyn. 255: 186-194.
94. Wilkie AOM. 2002. Why study human limb malformations? J Anat 202: 27-35.
95. Vega H, Waisfisz Q, Gordillo M, et al. 2005. Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. Nat Genet 37: 468-70.
96. Schule B, Oviedo A, Johnston K, et al. 2005. Inactivating mutations in ESCO2 cause SC Phocomelia and Roberts syndrome: no phenotypegenotype correlation. Am J Hum Genet 77: 1117-28.
97. Peltier AC, Russell JW. 2006. Advances in understanding druginduced neuropathies. Drug Saf 29: 23-30.
98. Cundari S, Cavaletti G. 2009. Thalidomide chemotherapy-induced peripheral neuropathy:actual status and new perspectives with thalidomide analogues derivatives. Mini Rev Med Chem 9: 760-68.
99. Rajkumar SV, Witzig TE. 2000. A Review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26: 351-62.
100. Raab MS, Podar K, Breitkreutz I, et al. 2009. Multiple myeloma. Lancet 374: 324-39.
101. Lu L, Payvandi F, Wu L, et al. 2009. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77: 78-86.
102. Castaneda CP, Zeldis JB, Freeman J, et al. 2008. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf 31: 743-52.